SCPS:OTC-Scopus Biopharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0002

Change

+0.00 (+100.00)%

Market Cap

USD 4.21K

Volume

175.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

-2.47 (-1.68%)

USD 649.39B
CMXHF CSL Limited

-1.79 (-0.93%)

USD 94.38B
CSLLY CSL Ltd

-0.44 (-0.45%)

USD 92.66B
UCBJY UCB SA ADR

-1.18 (-1.58%)

USD 27.94B
UCBJF UCB SA

N/A

USD 26.91B
ARGNF argenx SE

N/A

USD 23.04B
GNMSF Genmab A/S

+3.36 (+1.32%)

USD 17.89B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 6.87B
REGMF RemeGen Co. Ltd

N/A

USD 6.81B
IVBIY IVBIY

N/A

USD 6.79B

ETFs Containing SCPS

IEO 18.24 % 0.42 %

N/A

N/A
IOGP:LSE iShares Oil & Gas Explora.. 10.60 % 0.00 %

+0.32 (+0%)

USD 0.32B
SPOG:LSE iShares V Public Limited .. 10.60 % 0.00 %

+32.00 (+0%)

USD 0.32B
NRGD MicroSectors U.S. Big Oil.. 10.00 % 0.00 %

-10.31 (0%)

USD 0.09B
NRGU MicroSectors U.S. Big Oil.. 10.00 % 0.00 %

+27.94 (+0%)

USD 1.77B
NRGO 10.00 % 0.00 %

N/A

N/A
NRGZ 10.00 % 0.00 %

N/A

N/A
YGRN 10.00 % 0.00 %

N/A

N/A
FRAK 8.73 % 0.54 %

N/A

N/A
IESU:LSE iShares S&P 500 Energy Se.. 7.93 % 0.00 %

+13.88 (+0%)

USD 0.98B
JHME 6.90 % 0.48 %

N/A

N/A
NXF:CA First Asset Energy Giants.. 6.62 % 0.72 %

+0.07 (+0%)

CAD 0.15B
DIG ProShares Ultra Oil & Gas 6.23 % 0.95 %

+1.45 (+0%)

USD 0.10B
DDG 5.83 % 0.95 %

N/A

N/A
DUG ProShares UltraShort Oil .. 5.83 % 0.95 %

-0.39 (0%)

USD 0.02B
ERYY 4.79 % 0.45 %

N/A

N/A
WNRG:LSE SPDR MSCI World Energy UC.. 4.78 % 0.00 %

+0.61 (+0%)

USD 0.57B
XDW0:LSE db x-trackers MSCI World .. 4.76 % 0.00 %

+0.62 (+0%)

USD 1.14B
HUL-U:CA 4.46 % 0.00 %

N/A

N/A
HUL:CA 4.46 % 2.20 %

N/A

N/A
GASX 4.29 % 1.01 %

N/A

N/A
SXLE:LSE SPDR S&P U.S. Energy Sele.. 4.27 % 0.00 %

+0.50 (+0%)

USD 0.88B
GASL 1.45 % 1.19 %

N/A

N/A
TERM 0.88 % 0.64 %

N/A

N/A
SCHJ Schwab 1-5 Year Corporate.. 0.09 % 0.00 %

-0.02 (0%)

USD 0.40B
BWX SPDR® Bloomberg Internat.. 0.00 % 0.50 %

-0.08 (0%)

USD 0.86B
EBND SPDR® Bloomberg Emerging.. 0.00 % 0.41 %

-0.09 (0%)

USD 1.91B
MTUM 0.00 % 0.15 %

N/A

N/A
QUAL 0.00 % 0.15 %

N/A

N/A
TGED:CA TD Active Global Enhanced.. 0.00 % 0.00 %

-0.22 (0%)

CAD 0.27B
RYE 0.00 % 0.40 %

N/A

N/A
WIP SPDR® FTSE International.. 0.00 % 0.50 %

-0.20 (0%)

USD 0.39B
HPF:CA Energy Leaders Plus Incom.. 0.00 % 1.74 %

+0.03 (+0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -99.53% 2% F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.53% 2% F N/A F
Trailing 12 Months  
Capital Gain -99.61% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.61% 2% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -63.87% 1% F N/A F
Dividend Return -63.87% 1% F N/A F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.98% 72% C 57% F
Risk Adjusted Return -155.84% 2% F N/A F
Market Capitalization 4.21K 8% B- 5% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.